Pseudoprogression Associated With T-cell Infiltration During Tarlatamab Therapy for Small-Cell Lung Cancer: A Case Report.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: small-cell lung cancer treated with tarlatamab
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In this case, the peripheral blood lymphocyte count decreased, and the interleukin-6 level was markedly elevated, which was thought to reflect T-cell accumulation in the tumor. These trends in the blood tests may be useful in easily differentiating PsPD from true progressive disease during tarlatamab treatment.
Tarlatamab is a bispecific T-cell engager immunotherapy that targets delta-like ligand 3 and CD3.
APA
Ikeuchi T, Yamamoto M, et al. (2026). Pseudoprogression Associated With T-cell Infiltration During Tarlatamab Therapy for Small-Cell Lung Cancer: A Case Report.. Cureus, 18(2), e103393. https://doi.org/10.7759/cureus.103393
MLA
Ikeuchi T, et al.. "Pseudoprogression Associated With T-cell Infiltration During Tarlatamab Therapy for Small-Cell Lung Cancer: A Case Report.." Cureus, vol. 18, no. 2, 2026, pp. e103393.
PMID
41835784
Abstract
Tarlatamab is a bispecific T-cell engager immunotherapy that targets delta-like ligand 3 and CD3. We report a case of pseudoprogression (PsPD) in a patient with small-cell lung cancer treated with tarlatamab. Due to its mechanism, tarlatamab is known to induce T-cell infiltration into tumors. In PsPD, the tumor transiently enlarges because of massive T-cell accumulation within the tumor. In this case, the peripheral blood lymphocyte count decreased, and the interleukin-6 level was markedly elevated, which was thought to reflect T-cell accumulation in the tumor. These trends in the blood tests may be useful in easily differentiating PsPD from true progressive disease during tarlatamab treatment.